Frontlight ResearchEarly access
CompletedPhase 2
A Phase 2a, Randomised, Double-blind, Parallel and Placebo-controlled Trial Investigating Safety and Efficacy of LIB-01 in Treatment of Erectile Dysfunction
Key facts
- Who runs it
- Dicot AB
- Where
- Denmark, Netherlands, and Sweden6 sites in 3 countriesChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 140 people enrolled
- Started
- 7 Nov 2024
- Ended
- 19 Aug 2025
- Type of study
- Interventional
- Record updated
- 7 November 2024
Who can take part
- Age
- 18 years and older
- Sex
- Men only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 38 criteriaShow less
Who can take part
- Provision of signed and dated written informed consent prior to any trial specific procedures
- Male participant aged 25 to 65 years, inclusive, at the screening visit
- In a stable heterosexual relationship for at least 6 months prior to the screening visit
- Total score of 11-25 on questions 1-5 and 15 on the EF domain of the IIEF questionnaire
- Highly motivated to obtain treatment for ED
- Willing to abstain from unprotected sex, or willing to use condom to prevent drug exposure of a partner from first dose of IMP to 24 hours after the last dose. In addition, refrain from donating sperm from the date of dosing until 3 months after (last) dosing with the IMP. Any female partner of child-bearing potential of a non-vasectomised trial participant must use contraceptive methods with a failure rate of < 1% to prevent pregnancy until the end-of-trial visit. Participants in the Netherlands: Willing to abstain from unprotected sex and use condom to prevent drug exposure of a partner and pregnancy from first dose until the end-of-trial. In addition, refrain from donating sperm from the date of dosing until 3 months after (last) dosing with the IMP. Any female partner of child-bearing potential of a non-vasectomised trial participant must use contraceptive methods with a failure rate of < 1% to prevent pregnancy until the end-of-trial visit
- Understands the trial requirements
Who cannot take part
- Use of nitrate medications within 14 days prior to the screening visit
- Use of any drug with narrow therapeutic index or drugs that are sensitive substrates, strong inducers or strong inhibitors to CYP3A4 as well as substrates and inhibitors of OATP1B1 or sensitive to substrates to CYP2B6 in accordance with the list provided (see Section 9.6.2.1)
- Use of oral, injectable, intra-urethral, or topical pro-erectile drugs or supplements, including but not limited to PDE5-Is or prostaglandin E1, or use of devices for ED treatment, within 14 days prior to screening
- Plasma donation within one month of screening or blood donation (or corresponding blood loss) during the last three months prior to the screening visit
- Planned treatment or treatment with another investigational therapy (i.e., small molecule or biologic) within 3 months prior to the screening visit
- Any planned major surgery within the duration of the trial
- History of any clinically significant disease or disorder, including psychiatric disorder, which, in the opinion of the Investigator, may either put the participant at risk because of participation in the trial, or influence the results or the participant’s ability to participate in the trial
- History of Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
- History of prostatectomy
- History of alcohol abuse or excessive intake of alcohol, as judged by the Investigator
- Presence or history of drug abuse, as judged by the Investigator
- History of, or current use of anabolic steroids, as judged by the Investigator
- Bleeding deficiencies or ongoing anticoagulant therapy that would put the participant at risk, as judged by the investigator
- Uncontrolled cardiac disease within 6 months of screening, including but not limited to uncontrolled hypertension; unstable angina; myocardial infarction or cerebrovascular accident
- Type 1 diabetes
- Presence of penile anatomical abnormalities, such as penile fibrosis or Peyronie’s disease, which would cause significantly impaired sexual performance, as judged by the Investigator
- History of, or ongoing antiandrogen treatment
- Moderate to severe hepatic impairment at the time of the screening visit, as judged by the Investigator
- Any clinically significant illness, medical/surgical procedure or trauma within 4 weeks of the first administration of IMP
- Malignancy within the past 5 years, with the exception of in situ removal of basal cell carcinoma
- History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the Investigator, or history of hypersensitivity to drugs with a similar chemical structure or class to LIB-01 API
- History of priapism, or increased risk due to underlying illness, including but not limited to hemoglobinopathies such as sickle cell anaemia or thalassemia
- History of glaucoma
- Any positive result at the screening visit for serum hepatitis B surface antigen, hepatitis B and C antibodies and/or human immunodeficiency virus (HIV)
- Abnormal vital signs, laboratory test value or ECG of clinical significance, as judged by the Investigator
- Moderate to severe renal impairment with an eGFR (creatinine) ≤60 mL/min (revised Malmö-Lund equation)
- Haemoglobin A1c (HbA1c) ≥48 mmol/L (6.5%)
- Primary hypoactive sexual desire
- Insufficient therapeutic effect when using PDE5-Is
- Involvement in the planning, and/or conduct of the trial
- The Investigator considers the participant unlikely to comply with trial procedures, restrictions and requirements
This trial has no sites in United States.
It has sites in 3 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
To evaluate the efficacy of LIB-01 in the treatment of erectile dysfunction (ED). Safety objective: To evaluate the safety of LIB-01.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Record updated
- 7 November 2024